- Chemotherapy
- Radiotherapy
- Monoclonal Antibodies
- Stem Cell Transplantation
Follicular Lymphoma Treatment Market size was valued at USD 3.2 billion in 2022 and is poised to grow at a CAGR of 7.3% from 2023-2029. The follicular lymphoma treatment market is poised to grow at a significant rate owing to an increase in the R&D activities for the innovation of newer therapies and drugs. Most of the international players are actively involved in the development of newer products. For instance, in December 2015, Novartis announced phase IIa study results of CTL019 used in the treatment of certain types of lymphoma including follicular lymphoma. Moreover, the rising adoption of monoclonal antibodies for targeted therapies propels the follicular lymphoma treatment market. Furthermore, acquisitions and mergers, collaborations, product approvals, and product launchings are the strategies followed by the market players to gain a larger revenue share in the follicular lymphoma treatment market. For instance, in February 2017, Health Canada approved Roche Gazyva (Obinutuzumab) for patients with previously treated follicular lymphoma. In addition, in August 2017, Epizyme, Inc. and US Oncology Research collaborated to identify the non-Hodgkin lymphoma patients with EZH2 mutations, and eligible patients are directed to ongoing phase 2 clinical trial of Tazemetostast in diffuse large B-cell lymphoma and follicular lymphoma. Follicular lymphoma is the second most common indolent non-Hodgkin lymphoma and it develops when the body makes abnormal B-lymphocytes in lymph nodes. The symptoms associated with follicular lymphoma include enlargement of lymph nodes in neck, abdomen, and groin, weight loss, difficulties in breathing, fatigue, and night sweats. Follicular lymphoma is diagnosed by biopsy, blood tests, and X-rays among others. Follicular lymphoma can be treated with chemotherapy, radiation therapy, targeted therapy, and stem cell transplant.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Rise in prevalence of follicular lymphoma, family history of blood disorders, increase in R&D activities for the innovation of newer drugs, and technological advancements in disease diagnosis are anticipated to fuel the follicular lymphoma treatment market. Moreover, promising pipeline products, innovation of newer therapies such as monoclonal antibodies, and government initiations for the cancer management are expected to boost the market over the forecast period. However, stringent regulatory policies for drug approval, the high cost of treatment, and adverse effects associated with the treatment are expected to hamper the growth of follicular lymphoma treatment market over the forecast years.
The follicular lymphoma treatment market size was valued at USD 3.2 billion in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
Hoffmann La Roche Ltd. (Switzerland) Novartis AG (Switzerland) GlaxoSmithKline plc (U.K.) Merck & Co. Inc. (U.S.) AbbVie, Inc. (U.S.) Bayer AG (Germany)
1. Executive Summary |
2. Global Follicular Lymphoma Treatment Market Introduction |
2.1.Global Follicular Lymphoma Treatment Market - Taxonomy |
2.2.Global Follicular Lymphoma Treatment Market - Definitions |
2.2.1.Treatment Type |
2.2.2.Route of Administration |
2.2.3.End User |
2.2.4.Region |
3. Global Follicular Lymphoma Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Follicular Lymphoma Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Follicular Lymphoma Treatment Market By Treatment Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Chemotherapy |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Radiotherapy |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Monoclonal Antibodies |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Stem Cell Transplantation |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Follicular Lymphoma Treatment Market By Route of Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Parenteral |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Others |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Follicular Lymphoma Treatment Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Oncology Centers |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Academic Research Institutes |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8. Global Follicular Lymphoma Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Follicular Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Treatment Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Chemotherapy |
9.1.2.Radiotherapy |
9.1.3.Monoclonal Antibodies |
9.1.4.Stem Cell Transplantation |
9.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Parenteral |
9.2.3.Others |
9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Retail Pharmacies |
9.3.3.Oncology Centers |
9.3.4.Academic Research Institutes |
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10. Europe Follicular Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Chemotherapy |
10.1.2.Radiotherapy |
10.1.3.Monoclonal Antibodies |
10.1.4.Stem Cell Transplantation |
10.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Parenteral |
10.2.3.Others |
10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Retail Pharmacies |
10.3.3.Oncology Centers |
10.3.4.Academic Research Institutes |
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11. Asia Pacific (APAC) Follicular Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Chemotherapy |
11.1.2.Radiotherapy |
11.1.3.Monoclonal Antibodies |
11.1.4.Stem Cell Transplantation |
11.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Parenteral |
11.2.3.Others |
11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Retail Pharmacies |
11.3.3.Oncology Centers |
11.3.4.Academic Research Institutes |
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12. Middle East and Africa (MEA) Follicular Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Chemotherapy |
12.1.2.Radiotherapy |
12.1.3.Monoclonal Antibodies |
12.1.4.Stem Cell Transplantation |
12.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Parenteral |
12.2.3.Others |
12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Retail Pharmacies |
12.3.3.Oncology Centers |
12.3.4.Academic Research Institutes |
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13. Latin America Follicular Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
13.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Chemotherapy |
13.1.2.Radiotherapy |
13.1.3.Monoclonal Antibodies |
13.1.4.Stem Cell Transplantation |
13.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Parenteral |
13.2.3.Others |
13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Retail Pharmacies |
13.3.3.Oncology Centers |
13.3.4.Academic Research Institutes |
13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Hoffmann La Roche Ltd. (Switzerland) |
14.2.2.Novartis AG (Switzerland) |
14.2.3.GlaxoSmithKline plc (U.K.) |
14.2.4.Merck & Co. Inc. (U.S.) |
14.2.5.AbbVie, Inc. (U.S.) |
14.2.6.Bayer AG (Germany) |
14.2.7.Epizyme Inc. (U.S.) |
14.2.8.Bristol Myers Squibb (U.S.) |
14.2.9.Johnson and Johnson Services Inc. (U.S.) |
15. Research Methodology |
16. Appendix and Abbreviations |